4X1R

The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4

Summary for 4X1R

• Entry DOI: 10.2210/pdb4x1r/pdb
• Related: 4N1P 4N1Q 4N1S 4X0W 4X1N
• Descriptor: mupain-1-12, Urokinase-type plasminogen activator, 1-phenylguanidine, ... (4 entities in total)
• Functional Keywords: serine protease, peptidic inhibitor, upa, hydrolase inhibitor-hydrolase complex, hydrolase inhibitor/hydrolase
• Biological source: Homo sapiens (Human); More
• Cellular location: Secreted: P00749
• Total number of polymer chains: 2
• Total formula weight: 29110.15

Authors

Jiang, L.,Zhao, B.,Xu, P.,Andreasen, P.,Huang, M. (deposition date: 2014-11-25, release date: 2015-03-25, Last modification date: 2023-11-08)

Primary citation

Zhao, B.,Xu, P.,Jiang, L.,Paaske, B.,Kromann-Hansen, T.,Jensen, J.K.,Srensen, H.P.,Liu, Z.,Nielsen, J.T.,Christensen, A.,Hosseini, M.,Srensen, K.K.,Nielsen, N.C.,Jensen, K.J.,Huang, M.,Andreasen, P.A.
A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.
Plos One, 9:e115872-e115872, 2014

PubMed Abstract: Peptides are attracting increasing interest as protease inhibitors. Here, we demonstrate a new inhibitory mechanism and a new type of exosite interactions for a phage-displayed peptide library-derived competitive inhibitor, mupain-1 (CPAYSRYLDC), of the serine protease murine urokinase-type plasminogen activator (uPA). We used X-ray crystal structure analysis, site-directed mutagenesis, liquid state NMR, surface plasmon resonance analysis, and isothermal titration calorimetry and wild type and engineered variants of murine and human uPA. We demonstrate that Arg6 inserts into the S1 specificity pocket, its carbonyl group aligning improperly relative to Ser195 and the oxyanion hole, explaining why the peptide is an inhibitor rather than a substrate. Substitution of the P1 Arg with novel unnatural Arg analogues with aliphatic or aromatic ring structures led to an increased affinity, depending on changes in both P1 - S1 and exosite interactions. Site-directed mutagenesis showed that exosite interactions, while still supporting high affinity binding, differed substantially between different uPA variants. Surprisingly, high affinity binding was facilitated by Ala-substitution of Asp9 of the peptide, in spite of a less favorable binding entropy and loss of a polar interaction. We conclude that increased flexibility of the peptide allows more favorable exosite interactions, which, in combination with the use of novel Arg analogues as P1 residues, can be used to manipulate the affinity and specificity of this peptidic inhibitor, a concept different from conventional attempts at improving inhibitor affinity by reducing the entropic burden.

PubMed: 25545505
DOI: 10.1371/journal.pone.0115872

Experimental method

X-RAY DIFFRACTION (2.1 Å)